Derik De Bruin
Stock Analyst at B of A Securities
(3.79)
# 687
Out of 5,123 analysts
222
Total ratings
69.44%
Success rate
17.86%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Buy | $43 → $60 | $41.04 | +46.20% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $129.64 | +27.28% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,382.85 | +0.52% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $215.75 | +1.97% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $50.00 | -46.00% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $99.52 | +10.53% | 3 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $17.70 | -26.55% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $51.23 | -1.46% | 6 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $376.89 | -0.50% | 14 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $5.10 | +115.69% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $102.66 | -36.68% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $11.27 | +41.97% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $542.36 | +21.69% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $180.96 | +29.86% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $183.70 | +14.32% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $231.62 | +53.27% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $14.15 | +83.75% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $278.23 | -2.60% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $192.30 | -5.36% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $13.80 | +52.17% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $12.94 | +147.30% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $133.61 | -25.16% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $74.70 | +15.13% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.52 | +269.32% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.75 | +271.43% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $145.39 | +78.83% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $8.32 | +1,342.31% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $126.73 | -5.31% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $1.99 | +352.26% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $643.59 | -63.49% | 3 | Nov 2, 2018 |
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $41.04
Upside: +46.20%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $129.64
Upside: +27.28%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,382.85
Upside: +0.52%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $215.75
Upside: +1.97%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $50.00
Upside: -46.00%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $99.52
Upside: +10.53%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $17.70
Upside: -26.55%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $51.23
Upside: -1.46%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $376.89
Upside: -0.50%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $5.10
Upside: +115.69%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $102.66
Upside: -36.68%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $11.27
Upside: +41.97%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $542.36
Upside: +21.69%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $180.96
Upside: +29.86%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $183.70
Upside: +14.32%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $231.62
Upside: +53.27%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $14.15
Upside: +83.75%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $278.23
Upside: -2.60%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $192.30
Upside: -5.36%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $13.80
Upside: +52.17%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $12.94
Upside: +147.30%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $133.61
Upside: -25.16%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $74.70
Upside: +15.13%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.52
Upside: +269.32%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.75
Upside: +271.43%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $145.39
Upside: +78.83%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $8.32
Upside: +1,342.31%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $126.73
Upside: -5.31%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $1.99
Upside: +352.26%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $643.59
Upside: -63.49%